Review of the literature and a recent meta-analysis of 52 studies with more than 10000 patients contributes to a growing body of evidence indicating that the ACE-I/ARBs do not harm COVID-19 patients and in fact provide protective benefits by controlling the blood pressure which lowers the risk of mortality [57]. The gene discussed is ACE; the disease is COVID-19.